Biomerica Launches New Website For Its EZ Detect™ Colorectal Disease Screening Test
August 05 2021 - 8:19AM
Biomerica Inc. (NASDAQ: BMRA) today announced the launch of their
new website for their EZ Detect™ Colon Disease Test product at
https://ezdetect.com. The site features streamlined functionality
and easy access to essential and potentially life-saving
information about detection and treatment of colorectal diseases
including colon cancer. The new site is launching alongside a
digital health advertising and social media campaign to promote and
drive sales of Biomerica’s EZ Detect™ product. The Company is also
in discussions with major retailers to increase the U.S. and
international distribution of the EZ Detect™ Colon Disease Test by
adding the product to their online and in-store offerings.
Colorectal cancer is the second most common cause of cancer
deaths in the United States in men and women combined. It's
expected to cause about 52,980 deaths during 2021.[1]
The EZ Detect™ Colon Disease Test is the simplest in-home,
two-minute diagnostic test to detect hidden blood in the stool, one
of the primary early warning signs of colorectal disease. The test
does not require handling of stool or dietary restrictions. The
user simply drops a test pad onto the surface of the water in the
toilet bowl after a bowel movement. If blood is present in the
person’s stool, a blue-green indicator will appear on the test pad
within two minutes. The pad is then simply flushed down the
toilet.
In a Johns Hopkins University Study, EZ Detect™ was preferred
10:1 by patients over other fecal occult blood tests. Published
studies have also indicated that the best colorectal screening test
is “the one that gets done.” [2] Other Colorectal
screening tests all require handling of the stool, and delivering
or mailing the stool sample to a lab. This process results in a
high percentage of these competing tests never being performed by
patients. [3] EZ Detect™ does not require handling of the
stool.
Hidden blood in the stool can be caused by bleeding ulcers,
hemorrhoids, polyps, colitis, diverticulitis, fissures, rectal
cancer or colon cancer. Physicians, hospitals, and pharmacies
utilize or sell the EZ Detect™ test, which has no dietary
restrictions before or during the testing period.
“We are extremely excited to announce the launch of our new EZ
Detect™ Colon Test website,” commented Zack Irani, CEO of
Biomerica. “Our goal is to establish a modern, streamlined and
informative online presence combined with digital health
advertising and social media campaigns to drive awareness of the EZ
Detect™ product. We are also encouraged that major new retailers
are expressing strong interest in selling the EZ Detect™ product in
the United States and internationally. With all these exciting
events taking place, the new EZ Detect™ website will help educate
customers and drive sales through our existing and new retailer
partners.”
(NASDAQ: BMRA)Biomerica, Inc.
(www.biomerica.com) is a global biomedical technology company that
develops, patents, manufactures and markets advanced diagnostic and
therapeutic products used at the point of care (in home and in
physicians' offices) and in hospital/clinical laboratories for
detection and/or treatment of medical conditions and diseases. The
Company's products are designed to enhance the health and
well-being of people, while reducing total healthcare costs.
Biomerica’s primarily focus is on gastrointestinal and inflammatory
diseases where the Company has multiple diagnostic and therapeutic
products in development.
About InFoods®The Biomerica InFoods® IBS
product is designed to allow physicians to identify
patient-specific foods (e.g., eggs, broccoli, wheat, potatoes,
pork, etc.), that when removed from the diet, may alleviate or
improve an individual's IBS symptoms including, but not limited to,
constipation, diarrhea, bloating, pain and indigestion. This
patented, diagnostic-guided therapy is designed to allow for a
patient-specific, guided dietary regimen to improve IBS outcomes. A
point-of-care version of the product is being developed to allow
physicians to perform the test in-office using a finger stick blood
sample, while a clinical lab version of the product is expected to
be the first for which the company will seek regulatory approval. A
billable CPT code that can be used by both clinical labs and
physicians' offices is already available for
InFoods® products. Since the InFoods® product is a
diagnostic-guided therapy, and not a drug, it has no drug type side
effects. An estimated 40 million people in America currently suffer
from IBS making it a leading cause for patient doctor visits.
1. |
About Colorectal Cancer. Available from:
https://www.cancer.org/content/dam/CRC/PDF/Public/8604.00.pdf. |
2. |
Lansdorp-Vogelaar, I., A.B. Knudsen, and H. Brenner,
Cost-effectiveness of colorectal cancer screening - an overview.
Best Pract Res Clin Gastroenterol, 2010. 24(4): p.
439-49. |
3. |
Navarro, M., et al., Colorectal cancer population screening
programs worldwide in 2016: An update. World J Gastroenterol, 2017.
23(20): p. 3632-3642. |
The Private Securities Litigation Reform Act of 1995 provides a
"safe harbor" for forward-looking statements. Certain information
included in this press release (as well as information included in
oral statements or other written statements made or to be made by
Biomerica) contains statements that are forward-looking, such as
statements relating to the efficacy of the Company’s tests, FDA
clearance of the Company’s products, EUA clearance, the rapidity of
testing results, uniqueness of the Company’s products and
performance of these products as compared to competitors’ products,
test result accuracy of products, pricing of the Company’s test
kits, demand for domestic or international orders, retailer and
distributor interest in the Products, potential revenues from the
sale of current or future products, availability of the Company’s
test kits, and patent protection on any of the Company’s products
or technologies. Such forward-looking information involves
important risks and uncertainties that could significantly affect
anticipated results in the future, including, without limitation:
results of studies testing the efficacy of the Company’s tests,
including its COVID-19 tests, InFoods tests and other products;
regulatory approvals necessary prior to commercialization of the
Company’s products; availability of the Company’s test kits and
other products; capacity, resource and other constraints on our
suppliers; dependence on our third party manufacturers; dependence
on international shipping carriers; governmental import/export
regulations; demand for our various tests and other products;
competition from other similar products and from competitors that
have significantly more financial and other resources available to
them; governmental virus control regulations that make it difficult
or impossible for the company to maintain current operations;
regulations and regulatory clearance for the company’s
manufacturing facilities and other clearances needed to manufacture
and sell a medical related product, and the Company’s ability to
obtain patent protection on any aspects of its rapid test
technologies or other products. Accordingly, such results may
differ materially from those expressed in any forward-looking
statements made by or on behalf of Biomerica. Additionally,
potential risks and uncertainties include, among others,
fluctuations in the Company's operating results due to revenue
fluctuations, drop in demand for the Company’s products, changes in
its business model and expansion plans, downturns in international
and or national economies, the Company's ability to raise
additional capital, the competitive environment in which the
Company will be competing, and the Company's dependence on
strategic relationships. The Company is under no obligation to
update any forward-looking statements after the date of this
release.
Corporate Contact:
John Nesbett /Jennifer BelodeauIMS Investor
Relations203.972.9200jnesbett@institutionalms.com
Biomerica (NASDAQ:BMRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biomerica (NASDAQ:BMRA)
Historical Stock Chart
From Apr 2023 to Apr 2024